1. A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study. Issue 2 (February 2015) Authors: Kashiwagi, A.; Takahashi, H.; Ishikawa, H.; Yoshida, S.; Kazuta, K.; Utsuno, A.; Ueyama, E. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 2(2015:Feb.) Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double‐blind, placebo‐controlled study. Issue 3 (31st July 2014) Authors: Kashiwagi, A.; Kazuta, K.; Goto, K.; Yoshida, S.; Ueyama, E.; Utsuno, A. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 3(2015:Mar.) Page Start: 304 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗